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Objective: Primary squamous cell carcinoma (SCC) of the ovary in humans is rare. Most cases represent a
malignant transformation of ovarian teratoma, Brenner tumor, or endometriosis. The etiology of this
cancer remains largely unknown. Human papillomavirus (HPV) infection is a critical factor that induces
tumor formation, particularly cervical cancer. Therefore, this study aimed to evaluate the association of
HPV with malignant transformation of mature cystic teratoma (MCT) into SCC of the ovary.
Materials and methods: The samples included four formalin-ﬁxed parafﬁn-embedded SCC-MCT tissues
and their adjacent tissues from the cervix to the ovaries, 12 cases of benign teratoma ovarian tissues
(dermoid tissues), and 11 cases of benign nonteratoma ovarian tissues (nondermoid tissues). The two
squamous carcinoma tissues of the cervix were used as control samples. HPV was detected by immu-
nohistochemistry (IHC) with anti-HPV capsid or E6 (HPV type 16/18) antibodies and in situ hybridization
(ISH) with three sets of genotyping probes, HPV types 6/11, 16/18, and 31/33.
Results: IHC revealed HPV infection associated with the four cases of SCC-MCT and the two cases of control
cervical cancer samples. Importantly, HPV was also detected in adjacent reproductive tissues of the SCC-
MCT cases, which suggested that the viral particles might spread in an ascending route through the fal-
lopian tubes, endometrium, endocervix, and cervix to the ovaries. ISH revealed HPV type 16/18 in all SCC-
MCT cases and HPV type 31/33 in two, with no HPV type 6/11 in any SCC-MCT cases. However, compared
with the SCC-MCT cases, the lower detection rates of HPV in dermoid cysts and nondermoid tissues
suggested that HPV might not be associated with normal ovarian tissues or benign ovarian teratomas.
Conclusion: Our data suggest that high-risk HPV infection might be a causal factor that induces malig-
nant transformation of MCT into SCC of the ovary, although further investigation is still required.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Ovarian cancer is the ﬁfth leading cause of female cancer death
and has the highest mortality rate among all gynecological cancers
in the United States [1]. From 2007 to 2011, the annual ovarian
cancer incidence and death rates slowly decreased by 0.9% and 2.0%,ciences, National Sun Yat-Sen
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bstetrics & Gynecology. Publishedrespectively, in the United States [1]. However, in Taiwan, a study of a
30-year national population-based registry revealed an increasing
incidence and a decreasing age at diagnosis of ovarian cancer, which
is comparable to that found in other Asian countries [2].
Ovarian cancer represents a heterogeneous group of malignant
tumors of ovarian origin that may arise from germ cells, stromal
tissue, or epithelial tissue within the ovary. Most ovarian malig-
nancies are epithelial in origin (90%); the remaining 10% are germ-
cell tumors, sex-cord stromal tumors, soft-tissue tumors not spe-
ciﬁc to the ovary, metastatic tumors, and unclassiﬁed tumors [3].
A mature cystic teratoma (MCT), or dermoid cyst, is removed
with surgery and the condition is then cured. This type of germ-cell
tumor is common in women of childbearing age and might consist
of mature tissue originating from all three germ-cell layersby Elsevier Taiwan LLC. All rights reserved.
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tients with MCT are asymptomatic, pain and a sensation of
abdominal fullness can occur because of the mass; in some cases,
somatic malignant transformation of MCT can occur [6]. More than
80% of all malignant transformations of ovarian teratomas are
squamous cell carcinomas (SCCs) that arise from the ectoderm; the
rest are carcinoid tumors or adenocarcinomas [7e9]. Some cases of
SCC arising from the columnar epithelium through squamous
metaplasia have been reported [8]. Prolonged exposure to various
carcinogens in the female pelvic cavity might cause a malignant
change in MCT [10]. High levels of the tumor markers, including
SCC antigen, cancer antigen (CA) 125, CA19-9, and CA16-6, were
detected in MCT cases; SCC antigen and CA125 may be associated
with adverse outcomes [6,11].
Human papillomavirus (HPV) infection is considered a major
cause of infection-related cancers of the cervix uteri, vulva, vagina,
anus, oropharynx, and penis [12,13]. More than 100 types of HPV
have been identiﬁed, and at least 20 are associated with cervical
cancer [14e16]. HPV types 6 and 11 are low-risk or nononcogenic
viruses that cause benign or low-grade cervical cell abnormalities.
High-risk oncogenic types (such as types 16, 18, 31, and 33) can
cause cancers. Almost all cervical cancers are associated with high-
risk HPV infection. Worldwide, approximately one half of all cer-
vical cancers are caused by HPV type 16, and types 16 and 18
together account for approximately 70% of the cases. The oncogenic
impact of HPV type 16/18 is critical; however, a recent study in
Taiwan found that patients with high-grade squamous intra-
epithelial lesions were highly infected with high-risk HPV types
other than HPV 16/18. This suggests that high-risk HPV-type in-
fections other than type 16/18 should also be managed carefully
[17]. Although infection with a high-risk HPV type can cause cer-
vical cancer, the virus infection itself is not sufﬁcient to induce
cancer because cancer does not develop in most women with HPV
infection [15,18].
HPV detection in epithelial ovarian cancer has been inconsis-
tent. Polymerase chain reaction (PCR) ﬁndings are frequently
negative [19e23]; however, in situ hybridization (ISH) and immu-
nohistochemistry (IHC) revealed HPV infection in 52% of all
epithelial ovarian malignancy cases in Chinese women [24]. HPV
DNA could also be detected by Southern blot hybridization in
ovarian and endometrial tissues [25].
There are fewer conﬁrmed cases of high-risk HPV types in
ovarian SCC than in epithelial ovarian cancer [26e29]. Thus, un-
derstanding a possible association of HPV infection with SCC of
mature teratoma in Taiwan is important. In this study, we examined
the association of HPV infection in four MCT cases with malignant
transformation of MCT into SCC (SCC-MCT).
Materials and methods
Human tissue samples
We conducted a retrospective chart review. Patient information
was obtained from radiograph departments, operative reports, pa-
thology reports, and radiation oncology records. We identiﬁed only
four patients with SCC-MCT of the ovary treated at our institute in
Taiwan between 1990 and 2014. Formalin-ﬁxed parafﬁn-embedded
SCC-MCT tissues (tumor part tissues were identiﬁed by a patholo-
gist) of these four cases and their adjacent tissues from the cervix to
the ovaries were examined. We also examined samples from a
random selection of 11 normal (nondermoid) and 12 benign (der-
moid) ovary tissues for comparison. The study was approved by the
Institutional Review Board of Kaohsiung Veterans General Hospital
(Protocol Nos. VGHKS11-CT12-03 and VGHKS15-CT1-07) and con-
formed to the ethical principles of the Declaration of Helsinki.Cells
We examined HPV infection in the TC-1 cell line, an HPV-16
E6 and E7 and activated ras oncogene transfectant of primary
C57BL/6 mouse lung epithelial cells, kindly provided by T.C. Wu
(Johns Hopkins University, Baltimore, MD, USA) [30]. The cells
were maintained in Roswell Park Memorial Institute medium
supplemented with 10% fetal bovine serum (FBS), 2mM glutamine,
1mM sodium pyruvate, 20mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid, 100 IU penicillin/mL, and 100 mg
streptomycin/mL. HPV-negative C33A cells (Bioresource Collec-
tion and Research Center, Taipei, Taiwan) were grown in Dulbec-
co's Modiﬁed Eagle Medium supplemented with 10% FBS.
Immunohistochemistry
The UltraVision Quanto Detection System HRP Dab (Thermo)
was used for IHC analysis. In brief, parafﬁn-embedded tissue-
sample sections were prepared from parafﬁn-embedded tissue
blocks. Sections were dried overnight at 60C, deparafﬁnized, and
dehydrated with ethanol, and then incubated with blocking buffer
to avoid the background staining of nonspeciﬁc reaction with
endogenous peroxidase. Then, sections were incubated with the
monoclonal antibody for HPV capsid (SB24) or HPV 16/18 E6 pro-
tein (C1P5, sc-460; Santa Cruz Biotechnology, Santa Cruz, CA, USA)
overnight at 4C. The monoclonal antibody for HPV, clone SB24
(LifeSpan BioSciences, CA), reacts with an epitope of a major capsid
protein of HPV, which is broadly expressed among the various HPV
subtypes. Sections were then incubated with Primary Antibody
Ampliﬁer Quanto for 10 minutes at room temperature, and then
with HRP Polymer Quanto for 10 minutes. The horseradish perox-
idase (HRP) substrate diaminobenzidine (DAB) was added to
generate a brown polymeric oxidation product. Sections were then
counterstained with hematoxylin. The HPV capsid protein signal
was observed under a microscope.
In situ hybridization
Detection involved parafﬁn-embedded ovarian or cervix cancer
tissue sections as described previously [31,32]. Deparafﬁnized and
hydrated sections were stained with biotin-labeled HPV 6/11, 16/18,
or 31/33 DNA probes (PanPath REMBRANDT DISH-HRP detection
kit for HPV types, Amsterdam, The Netherlands) according to the
manufacturer's instructions and rinsed several times in Trisesaline;
hybridization was then visualized using DAB (Thermo) as a sub-
strate of HRP. Sections were counterstained with hematoxylin. Af-
ter tapping off the excess counterstain and brieﬂy rinsing in
distilled or deionized water, sections were mounted on slides using
an aqueous mounting medium and viewed under a microscope.
Statistical analysis
Statistical analysis involved the use of GraphPad Prism 5
(GraphPad Software, La Jolla, CA, USA). Chi-square test was used to
test differences in HPV infection among dermoid, nondermoid cyst,
and SCC-MCT tissues.
Results
Four SCC-MCT cases
The ﬁrst case was a 32-year-old woman, gravida 0, para 0, who
presented a continual “full” feeling. The diagnosis was a right
ovarian cystic teratoma. The patient underwent exploratory lapa-
rotomy with right salpingo-oophorectomy. Pathologic analysis
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(FIGO) Stage Ia SCC-MCT. The patient underwent six courses of
chemotherapy and second-look surgery with bilateral pelvic lymph
node dissection. No residual disease was detected, and none of the
18 lymph nodes contained malignant cells. Currently, she is alive
with no evidence of disease.
The second case was a 54-year-old woman, gravida 4, para 4,
who had a 4-week history of a palpable abdominal mass. She
received a diagnosis of ovarian malignancy and underwent optimal
debulking surgery. She had a 16-cm left ovarian mass with mild
ascites and enlarged bilateral pelvic lymph nodes. Pathologic
analysis revealed SCC-MCT and metastatic disease in the lymph
nodes of the pelvis (8/25) and para-aorta (1/3); however, peritoneal
cytology and the remaining staging investigation gave negative
results. The patient underwent ﬁve courses of adjuvant chemo-
therapy. She presented 18 months later with liver and lung
metastasis and died 6 months later.
The third case was a 39-year-old woman, gravida 3, para 2, who
complained of abdominal bloating for 4 weeks. She received a
diagnosis of left ovarian dermoid cyst rupture with highly malig-
nant potential on ultrasonography and computed tomography.
Exploratory laparotomy revealed an 18-cm left ovarian mass with
abdominal carcinomatosis, severe pelvic adhesion, and massive
ascites. Suboptimal debulking surgery was performed. Pathology
revealed SCC-MCTwith pelvic lymph nodemetastasis (2/27 nodes).
The tumor ruptured preoperatively because of abdominal carci-
nomatosis. The patient underwent adjuvant chemotherapy with
taxol, carboplatin, and ifosfamide. The levels of serum SCC antigen
were immediately increased to 20 ng/mL (normal range 0e1.5 ng/
mL) after three courses of chemotherapy. The patient underwent
one-time adjuvant radiation therapy but died 6 months later
because of urosepsis.
The fourth case was a 49-year-old woman, gravida 1, para 1,
who complained of abdominal pain for 1 day. She received a
diagnosis of a right ovarian dermoid cyst with torsion by ultra-
sonography. She underwent urgent laparoscopic unilateral
salpingo-oophorectomy, and a 16-cm right ovarian mass was
discovered. The pathology report showed SCC-MCT. The patient
received a diagnosis of FIGO Stage Ia. She is still alive and regularly
visits our outpatient clinic.
The tumors of the four patients were predominantly cystic, ﬁlled
with pultaceous material, and hair. Foci of solid areas were iden-
tiﬁed. All tumors showed keratinized stratiﬁed squamous epithe-
lium, hair follicles, sebaceous glands, lobules of mature cartilage,
glands lined with respiratory mucosa, and skeletal muscle. The
clinical data are presented in Table 1.Table 1
Clinical characteristics and outcome of the four cases of squamous cell carcinoma with m
Case
no.
Age
(y)
FIGO
Stage
Ultrasonography/computed tomography;
tumor diameter (cm)
Tumor markersa
1 32 Ia Large ovarian cyst, r/o dermoid
cyst/postoperative negative ﬁndings; 18
CEA: 5, SCC: 0.3
CA125: 68.2, CA1
Cytology: not do
2 54 IIIc Large ovarian tumor, r/o malignancy/ovary
tumor, r/o malignancy; 16
CEA: 23, CA199:
AFP: <3
Cytology: Negati
3 39 IIIc Large ovarian cyst, r/o dermoid cyst
with pelvic adhesion/dermoid cyst rupture
and malignancy transformation must be
considered; 18
CEA: 2, SCC: 9.2
CA125: 57.7, CA1
Cytology: Negati
4 49 Ia Large dermoid cyst r/o torsion; 16 SCC: Nil
CA125: Nil, CA19
AFP ¼ alpha-fetoprotein; CA ¼ cancer antigen; CEA ¼ carcinoembryonic antigen; DOD
LNs ¼ lymph nodes; MCT ¼ mature cystic teratoma; NED ¼ no evidence of disease; r/o ¼
a Initial diagnosis.IHC of HPV
We subjected four SCC-MCT and two squamous carcinoma
samples of the cervix to IHC with antibody for HPV capsid protein.
Capsid protein was found in all sections, with strong signaling in
Case 2 and control-sample cervical tissue 1 (Figure 1A). HPV 16 was
found in epithelial ovarian cancer [31], and therefore, we investi-
gated E6 protein expression of the high-risk HPV type 16/18. The
HPV 16/18 E6 protein was detected in all SCC-MCT cases and cer-
vical cancer tissues (Figure 1B). We conﬁrmed the accuracy of IHC
ﬁndings using HPV 16 E6-positive TC1 cells (HPV-16 E6 and E7 and
c-Ha-ras oncogene-transfected primary lung epithelial cells of
C57BL/6 mice [30]) and HPV-negative C33A cells (cervical cancer
biopsy-derived cells [33]). In IHC analysis, TC-1 and C33A cells were
negative for anti-HPV capsid (Figure 1C); however, TC-1 cells were
positive for anti-HPV-16/18 E6, but C33A cells were negative
(Figure 1D).
We tested the tissue distribution of HPV infection in the SCC-
MCT samples, cervical cancer tissues, as well as their adjacent tis-
sues from reproductive organs and associated pelvic and para-
aortic lymph nodes taken during surgery. HPV capsid and HPV
16/18 E6 proteins were highly detected in the tested samples,
which suggested broad HPV infection in the reproductive system of
SCC-MCT and cervical cancer patients (Table 2). The selected posi-
tive IHC images of SCC-MCT Case 1 are presented in Figure 2 (data
of other tested samples are not shown). Our ﬁnding suggested that
the HPV particles might spread through the reproductive system by
an ascending route through the fallopian tubes, endometrium,
endocervix, and cervix to the ovaries.
Furthermore, 12 dermoid cyst and 11 nondermoid cyst tissues
were subjected to IHC with anticapsid and anti-E6 HPV antibody.
Cases 4, 5, and 6 of dermoid cyst were positive for HPV capsid, and
no HPV E6-positive case was identiﬁed (Figure 3A). Case 7, with a
nondermoid cyst, was positive for HPV capsid and E6 (Figure 3B).
Compared with the 95% HPV capsid detection rate (all 24 samples
from the 4 SCC-MCT cases), the dermoid cyst and nondermoid cyst
samples showed signiﬁcantly lower detection rates of 25% and 9%,
respectively (Table 3). Similar results were shown with regard to
anti-E6 HPV antibody: 96% of SCC samples were positive for HPV
type 16/18 E6, but only 0% of dermoid and 9% of nondermoid cyst
samples were positive for this type (Table 3). The lack of ﬁndings for
anti-E6 positivity in dermoid cysts may due to infection with types
of HPV other than type 16/18. Taken together, this evidence sug-
gests that HPV infection in the reproductive system by an ascending
route might play a role in the malignant transformation of a benign
dermoid cyst into an SCC.ature cystic teratoma (SCC-MCT).
/cytology Operation type/ascites LNs Outcome
99: 69
ne
RSO/Nil Bilateral pelvic: 0/18
(second-look operation)
NED (164 mo)
206
ve
Optimal debulking/little Right pelvic: 0/11
Left pelvic: 8/14
Para-aortic: 1/3
DOD (24 mo)
99: 87.7
ve
Suboptimal
debulking/2400 mL
Right pelvic: 0/10
Left pelvic: 2/17
Para-aortic: 0/1
DOD (6 mo)
9: Nil
RSO/Nil Nil Alive (37 mo)
¼ dead of disease; FIGO ¼ International Federation of Gynecology and Obstetrics;
removal of; RSO ¼ right salpingo-oophorectomy; SCC ¼ squamous cell carcinoma.
Figure 1. Human papillomavirus (HPV) diagnosis by immunohistochemical (IHC) analysis. (A,B) HPV infection in four cases (Cases 1e4) of squamous cell carcinoma with mature
cystic teratoma (SCC-MCT) and two samples of cervical cancer tissue (Cases 1 and 2) detected by IHC with antibodies for HPV capsid protein and HPV 16/18 E6 protein. (C,D) IHC
detection of HPV capsid and E6 in TC1 and C33A cells. TC1 cells are capsid-negative and E6-positive cells. C33A cells are HPV-negative cells that do not express HPV capsid and E6
proteins.
Table 2
Human papillomavirus detection by immunohistochemistry in tissue biopsies of cancer patients.
Case no. Total
tissue no.
Anticapsid (þ)
no. (%)
Anti-E6 (þ)
no. (%)
Positive rate of anticapsid antibody Positive rate of anti-E6 antibody
SCC-MCT 1 17 15 (88) 16 (94) L't SCC-MCT (5/7), R't ovary (1/1), uterus (1/1),
cervix (1/1), endometrium (1/1), myometrium (1/1),
fallopian tube (0/1),
R't pelvic LNs (1/1), L't pelvic LNs (1/1),
para-aortic LNs (1/1), omentum (1/1)
L't SCC-MCT (6/7), R't ovary (1/1), uterus (1/1),
cervix (1/1), endometrium (1/1), myometrium (1/1),
fallopian tube (0/1), R't pelvic LNs (1/1),
L't pelvic LNs (1/1), para-aortic LNs (1/1),
omentum (1/1)
SCC-MCT 2 19 18 (95) 18 (95) SCC-MCT (4/4), gray-white polypoid tumor (1/1),
uterus (1/1), R't bilateral ovaries (1/1),
L't bilateral ovaries (1/1),
R't bilateral fallopian tubes (1/1),
L't bilateral fallopian tubes (1/1), vaginal cuff (1/1),
uterine cervix (1/1), bilateral parametrium (1/1),
endometrium (1/1), ovary and fallopian tubes (1/1),
bilateral pelvic (1/1), para-aortic LNs (2/3)
SCC-MCT (4/4), gray-white polypoid tumor (1/1),
uterus (1/1), R't bilateral ovaries (1/1),
L't bilateral ovaries (1/1),
R't bilateral fallopian tubes (1/1),
L't bilateral fallopian tubes (1/1), vaginal cuff (1/1),
uterine cervix (1/1), bilateral parametrium (1/1),
endometrium (1/1), ovary and fallopian tubes (1/1),
bilateral pelvic (1/1), para-aortic LNs (2/3)
SCC-MCT 3 16 15 (94) 15 (94) SCC-MCT (5/5), cervix (2/2), endometrium (1/1),
nontumor ovarian (1/1), omentum (1/1),
colon tumor (0/1), peritoneum (1/1), appendix (1/1),
R't pelvic LNs (1/1), L't pelvic LNs (1/1),
para-aortic LNs (1/1)
SCC-MCT (5/5), cervix (2/2), endometrium (1/1),
nontumor ovarian (1/1), omentum (1/1),
colon tumor (0/1), peritoneum (1/1), appendix (1/1),
R't pelvic LNs (1/1), L't pelvic LNs (1/1),
para-aortic LNs (1/1)
SCC-MCT 4 8 8 (100) 8 (100) SCC-MCT (8/8) SCC-MCT (8/8)
Cervical
cancer 1
16 15 (94) 15 (94) Cervical tumor (4/4), vaginal cuff (1/1),
R't parametrium (1/1), endometrium (1/1),
R't ovary and tube (1/1), R't common iliac LNs (1/1),
R't external iliac LNs (1/1), R't internal iliac LNs (0/1),
R't obturator LNs (1/1), L't external iliac LNs (1/1),
L't internal iliac LNs (1/1),
L't obturator LNs (1/1), para-aortic LNs
Tumor (4/4), vaginal cuff (1/1), R't parametrium (1/1),
endometrium (1/1), R't ovary and tube (1/1),
R't common iliac LNs (1/1), R't external iliac LNs (1/1),
R't internal iliac LNs (0/1), R't obturator LNs (1/1),
L't external iliac LNs (1/1), L't internal iliac LNs (1/1),
L't obturator LNs (1/1), para-aortic LNs
Cervical
cancer 2
4 4 (100) 4 (100) Cervix tumor (2/2), R't parametrium (2/2) Tumor (2/2), R't parametrium (2/2)
L't ¼ left; LNs ¼ lymph nodes; MCT ¼ mature cystic teratoma; R't ¼ right; SCC ¼ squamous cell carcinoma.
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Figure 2. Positive IHCdataof Case1 SCC-MCTandadjacent tissues. IHC analysiswith anti-
HPV capsid and E6 protein was performed in tissues including multiple SCC-MCT tissue
blocks as indicated. HPV ¼ human papillomavirus; IHC ¼ immunohistochemistry;
L't¼ left; LNs¼ lymphnodes;MCT¼mature cystic teratoma; R't¼ right; SCC¼ squamous
cell carcinoma.
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The IHC data showed the HPV capsid and HPV 16/18 E6
detected in the tissue samples of SCC-MCT and adjacent tissues
and cervical cancers. It would be important to demonstrate that
HPV DNA existed in those specimens; thus, we used the well-
established method of ISH analysis for HPV DNA detection [26].
The ISH probes targeting high-risk oncogenic HPV types, types
16/18 and 31/33, and low-risk or nononcogenic HPV types, 6/11,
were used to demonstrate that the HPV DNA was incorporated
into the cell nucleus. Our data revealed that HPV type 16/18, but
not HPV type 6/11, DNA was found in the four SCC-MCT samples,
and HPV type 31/33 DNA, high-risk HPV types associated with
cervical cancer, was detected in SCC-MCT Cases 2 and 3
(Figure 4). This result revealed co-infection with multiple high-
risk types of HPV in ovarian tissue. Two cervical cancer sam-
ples were positive for HPV 16/18, and HPV 6/11 DNA was found in
one sample (Figure 4). The ISH results were consistent with IHC
data (Figure 1).Discussion
Primary SCC of the ovary is rare. Most cases represent malignant
transformation of ovarian teratoma, Brenner tumor, or endome-
triosis. In this study, we described four cases of ovarian teratoma
with malignant transformation of MCT into SCC. We detected HPV
infection in SCC-MCT ovarian samples by IHC and ISH, which sug-
gests that HPV infection is associated with SCC-MCT in ovary der-
moid cysts. HPV infection was also detected in adjacent
reproductive tissues of the SCC-MCT cases, which suggests that the
viral particles might spread within the reproductive system. The
lower detection rates of HPV in dermoid and nondermoid cysts
indicate that HPV might not be associated with normal or benign
ovarian teratomas. However, whether HPV causes malignant
transformation of benign dermoid cysts into SCC remains to be
further explored.
HPV plays a causal role in cervical cancer. HPV infection is also
detected in other cancers of the female lower genital tract,
including cancers of the vulva, vagina, and perineum [13,15,34].
However, the role of HPV in the pathogenesis of ovarian cancer is
controversial, and the results are conﬂicting. Two systematic
reviews noted the geographical variation in HPV prevalence in
epithelial ovarian cancer tissue [35,36]. Overall, HPV prevalence
in patients with ovarian cancer was found to be 15.5e17%: 0% in
North America, 4.0e18.5% in Europe, and 31.4e45.6% in Asia.
Four HPV types, types 6, 16, 18, and 33, were found in ovarian
cancer; HPV type 16 was the most common, with a prevalence of
39.7%, followed by type 18 [35,36]. HPV does not play an
important role in Western European and North American pop-
ulations but may have a role in other populations, although HPV-
mediated ovarian epithelial tumorigenesis remains inconclusive
[37e39].
To the best of our knowledge, only four conﬁrmed cases of
high-risk HPV types have been reported in ovarian SCC. The ﬁrst
was case was reported in 1996 in a 40-year-old Canadian woman
who had SCC-MCT, recurrent high-grade intraepithelial neoplasia
of the vulva, and high-grade cervical intraepithelial neoplasia;
HPV type 16/18 DNA was identiﬁed by ISH in the invasive carci-
noma in the left ovary [26]. A second case was reported in the
United States, where a 55-year-old woman who had in situ SCC of
the cervix with contiguous metastasis and invasion of the endo-
metrium, fallopian tubes, and ovaries; untyped HPV DNA was
detected by PCR in SCC tissues [28]. The third case was from the
United Kingdom; in 1998, a 52-year-old woman received a diag-
nosis of synchronous ovarian and cervical SCC; staining was
positive for HPV-16 E6 [27]. A fourth case of HPV infection was
identiﬁed by pan HPV IHC staining in a 48-year-old woman with
SCC-MCT in Belgium in 2007 [29]. We herein presented four
additional SCC-MCTcases associated with high-risk HPV infection.
This report is the ﬁrst account of HPV associated with ovarian SCC
in Taiwan. The previous and present cases suggest that HPV may
be involved in the development of ovarian SCC. Nevertheless,
there are also four reported SCC-MCT cases that were negative for
HPV [22,40e42]. It was thought that the low sensitivity of the
techniques might result in a failure to demonstrate the presence
of HPV in SCC-MCT [26]. Therefore, a large cohort study with HPV
sequence typing should be conducted to validate the oncogenic
role of HPV in SCC-MCT.
Our ﬁndings of positive HPV from ovarian squamous and female
genital tract tissues are similar to a previous case of SCC-MCT in the
same area [28]. In addition, a PCR-based study found HPV 16/18
DNA in Hong Kong Chinese women with endometrial carcinomas
and primary epithelial ovarian cancer [38]. Thus, the upper genital
tract may be susceptible to HPV infection. The virus particles likely
spread in an ascending route through the fallopian tubes,
Figure 3. Human papillomavirus (HPV) detection in dermoid and nondermoid ovarian tissues. Immunohistochemical (IHC) analysis of HPV capsid and type 16/18 E6 in (A) 12
dermoid and (B) 11 nondermoid cyst samples from the right or left ovary. R't ¼ right; L't ¼ left; (þ) ¼ positive IHC staining; () ¼ negative IHC staining.
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tion is further supported by our ﬁnding of HPV positivity in tissues
from the ovarian dermoid cyst, suggesting retrograde passage along
the genital tract of tissues and the involvement of viral particles
that facilitated the development of squamous lesions in the ovary.
Comparison of the low positive rate of HPV infection in dermoid
and nondermoid cysts with a high positive rate of HPV infection in
SCC-MCT tissues and their adjacent tissues revealed an associationbetween HPV infection and malignant transformation of teratoma.
It would be important to understand whether HPV infection is
correlated with poor prognosis of ovarian teratomas.
Because this is a retrospective study, the specimens were pre-
pared from parafﬁn-embedded tissues for ISH and IHC analysis. The
DNA extraction, PCR, and sequencing were poorly implemented
because of the limited tissue blocks. However, the applied methods
(IHC and ISH) are well established [26,27]. In addition, the
Table 3
HPV detection by immunohistochemical analysis in dermoid and nondermoid
cyst tissues.
Tumor type Total sample no.a Anticapsid (þ) (%) Anti-E6 (þ) (%)
Dermoid cyst
(12 patients)
12 3 (25) 0 (0)
Nondermoid cyst
(11 patients)
11 1 (9) 1 (9)
SCC-MCT
(4 patients)a
24 22 (92) 23 (96)
Anticapsid, p < 0.001, c2 test; anti-E6, p < 0.001, c2 test.
HPV ¼ human papillomavirus; MCT ¼ mature cystic teratoma; SCC ¼ squamous
cell carcinoma.
a One sample from each case of dermoid and nondermoid tissues was analyzed.
The number of tested SCC-MCT tissue blocks (tumor part) from the four SCC-MCT
cases is as follows: Case 1, seven blocks; Case 2, four blocks; Case 3, ﬁve blocks;
Case 4, eight blocks.
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sequencing. In this study, all cases of SCC-MCT (4 patients) diag-
nosed in our hospital were included; to further validate the role of
HPV in SCC-MCT development, a nationwide large-scale cohort trial
should be conducted in the future. An investigation with freshFigure 4. Human papillomavirus (HPV) detection by in situ hybridization (ISH). HPV
infection in four cases of SCC-MCT and two samples of cervical cancer tissue detected
by ISH with DNA probes HPV 6/11, 16/18, and 31/33. The arrows indicate the positive
ISH signals of HPV DNA. MCT ¼ mature cystic teratoma; SCC ¼ squamous cell
carcinoma.surgical specimens will also allow the sequencing analysis of HPV
typing.
Validating the role of HPV in SCC or other cell types of ovarian
cancer may support HPV vaccination to reduce the incidence of
ovarian cancer. However, further studies are required to determine
the exact role of HPV in the etiology of this condition.
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